AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22071008 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Number of subjects: 18
Study 22071008 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 19874051 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody self‐oriented immunoprobe on magnetic nanoparticles (MNPs)
Number of subjects: 0
Study 19874051 — intervention group
Group type: COMPARATOR
Intervention: BA‐mediated covalent antibody immobilization
Number of subjects: 0
Study 19874051 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple immunoassay using the new immunonanoprobe
Number of subjects: 0
Study 17497543 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Realization treatment
Number of subjects: 0
Study 17497543 — intervention group
Group type: COMPARATOR
Intervention: 12-Step treatment
Number of subjects: 0
Study 15018625 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (Botox®) injections
Number of subjects: 0
Study 15018625 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 0
Study 12390854 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEI)
Number of subjects: 36
Study 12390854 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blocker or alpha-receptor blocker (Control)
Number of subjects: 36
Study 9661601 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg sublingually)
Number of subjects: 2
Study 9661601 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (25 mg i.v. bolus)
Number of subjects: 2
Study 9661601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 9661601 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside or nicotine
Number of subjects: 2
Study 7631600 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation monitoring including single daily estimation of PTF1 + 2 (target range < 0.5 nmol/L) and FII activity (15% to 35%); adjustment of heparin and phenprocoumon dosages based on PTF1 + 2 and FII measurements.
Number of subjects: 120
Study 7631600 — intervention group
Group type: COMPARATOR
Intervention: Standard coagulation tests (TT, aPTT, INR, AT III, fibrinogen) for anticoagulation monitoring.
Number of subjects: 120
Study 2076373 — intervention group
Group type: EXPERIMENTAL
Intervention: UVAB rays (350 +/‐ 32 nm)
Number of subjects: 10
Study 2076373 — intervention group
Group type: COMPARATOR
Intervention: UVB rays (300 +/‐ 5 nm)
Number of subjects: 10
Study 7448680 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (1 g per day)
Number of subjects: 16
Study 7448680 — intervention group
Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 16
Study 30915633 — intervention group
Group type: EXPERIMENTAL
Intervention: HCAG chemotherapy
Number of subjects: 98
Study 30915633 — intervention group
Group type: COMPARATOR
Intervention: FLAG chemotherapy
Number of subjects: 98
Study 28239295 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care intervention
Number of subjects: 96
Study 28239295 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (control)
Number of subjects: 96
Study 27858735 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA)
Number of subjects: 33
Study 27858735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 24629480 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral cessation treatment (1 in-person session and 3 phone calls)
Number of subjects: 50
Study 24629480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral cessation treatment (3 in-person sessions and 5 phone calls)
Number of subjects: 50
Study 24629480 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (brief and intensive)
Number of subjects: 50
Study 22606232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 55
Study 22606232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 18710702 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (1.5 mg)
Number of subjects: 0
Study 17684654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 24
Study 17684654 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 24
Study 14504956 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down implementation of health regulations regarding rest times
Number of subjects: 440
Study 14504956 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer rest times during high season
Number of subjects: 440
Study 11784873 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-calcium, low-animal-protein, low-salt diet (30 mmol calcium, 52 g animal protein, 50 mmol sodium chloride)
Number of subjects: 120
Study 11784873 — intervention group
Group type: COMPARATOR
Intervention: Low-calcium diet (10 mmol calcium)
Number of subjects: 120
Study 9744372 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% applied once daily for 6 months
Number of subjects: 223
Study 9744372 — intervention group
Group type: COMPARATOR
Intervention: Switching from timolol to latanoprost
Number of subjects: 223
Study 9744372 — intervention group
Group type: COMPARATOR
Intervention: Timolol treatment
Number of subjects: 223
Study 9744372 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost treatment
Number of subjects: 223
Study 8553147 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg once daily
Number of subjects: 19
Study 8553147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2916889 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily normal saline irrigation
Number of subjects: 32
Study 2916889 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (control)
Number of subjects: 32
Study 1097596 — intervention group
Group type: EXPERIMENTAL
Intervention: benztropine
Number of subjects: 18
Study 1097596 — intervention group
Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 18
Study 1097596 — intervention group
Group type: COMPARATOR
Intervention: chlorpromazine
Number of subjects: 18
Study 29939302 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (fructooligosaccharide, FOS, 12 g/day)
Number of subjects: 50
Study 29939302 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 12 g/day)
Number of subjects: 50
Study 28812167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic (5-ALA) followed by 595-nm pulsed dye laser therapy (5-ALA PDL)
Number of subjects: 181
Study 28812167 — intervention group
Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser therapy alone (PDL alone)
Number of subjects: 181
Study 25842221 — intervention group
Group type: COMPARATOR
Intervention: Injectable procaine benzylpenicillin-gentamicin for 7 days (group A)
Number of subjects: 3564
Study 25842221 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable gentamicin and oral amoxicillin for 7 days (group B)
Number of subjects: 3564
Study 25842221 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable procaine benzylpenicillin-gentamicin for 2 days, then oral amoxicillin for 5 days (group C)
Number of subjects: 3564
Study 25842221 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable gentamicin for 2 days and oral amoxicillin for 7 days (group D)
Number of subjects: 3564
Study 25842221 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 3564
Study 23433966 — intervention group
Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 537
Study 23433966 — intervention group
Group type: COMPARATOR
Intervention: Established lifestyle recommendations
Number of subjects: 537
Study 23433966 — intervention group
Group type: COMPARATOR
Intervention: Established lifestyle recommendations plus Dietary Approaches to Stop Hypertension dietary pattern
Number of subjects: 537
Study 23433966 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in dietary self-efficacy (DSE)
Number of subjects: 537
Study 23433966 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in exercise self-efficacy (ESE)
Number of subjects: 537
Study 22035508 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pirfenidone (1800 mg/day)
Number of subjects: 0
Study 22035508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pirfenidone (1200 mg/day)
Number of subjects: 0
Study 22035508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19645171 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral-Sciatic Nerve Block (FSB)
Number of subjects: 56
Study 19645171 — intervention group
Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 56
Study 17919161 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based interactive postpartum sexual health education programme (experimental group, n = 84)
Number of subjects: 166
Study 17919161 — intervention group
Group type: COMPARATOR
Intervention: Routine postpartum teaching (control group, n = 82)
Number of subjects: 166
Study 15126738 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont maneuver
Number of subjects: 156
Study 15126738 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 156
Study 15126738 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 156
Study 15126738 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont maneuver, Flunarizine, No treatment
Number of subjects: 156
Study 11324149 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT focussed on the calcified region
Number of subjects: 50
Study 11324149 — intervention group
Group type: COMPARATOR
Intervention: ESWT focussed on the insertion of the supraspinatus tendon
Number of subjects: 50
Study 9207580 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 0
Study 9207580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9207580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 8281528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10‐20 mg twice daily)
Number of subjects: 0
Study 8281528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10‐20 mg once daily)
Number of subjects: 0
Study 8281528 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 3732378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline administered 1 h prior to food
Number of subjects: 18
Study 3732378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline administered with a standard breakfast
Number of subjects: 18
Study 3732378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline administered 1 h after a standard breakfast
Number of subjects: 18
Study 3732378 — intervention group
Group type: COMPARATOR
Intervention: Cibenzoline under fasting conditions
Number of subjects: 18
Study 31567375 — intervention group
Group type: EXPERIMENTAL
Intervention: T-180 mg-24 h
Number of subjects: 102
Study 31567375 — intervention group
Group type: EXPERIMENTAL
Intervention: T-90 mg-24 h
Number of subjects: 102
Study 31567375 — intervention group
Group type: EXPERIMENTAL
Intervention: T-90 mg-12 h
Number of subjects: 102
Study 31567375 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 102
Study 29943831 — intervention group
Group type: EXPERIMENTAL
Intervention: DRL_BZ
Number of subjects: 149
Study 29943831 — intervention group
Group type: COMPARATOR
Intervention: RMP
Number of subjects: 149
Study 29943831 — intervention group
Group type: COMPARATOR
Intervention: RP
Number of subjects: 149
Study 27126300 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 51
Study 27126300 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 51
Study 25092564 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT plus thalidomide (5 mg/kg)
Number of subjects: 43
Study 25092564 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT plus thalidomide (8 mg/kg)
Number of subjects: 43
Study 25092564 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT plus thalidomide (10 mg/kg)
Number of subjects: 43
Study 25092564 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT plus thalidomide (all doses)
Number of subjects: 43
Study 22610355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin (NDP) at AUC 12
Number of subjects: 15
Study 22610355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin (NDP) calculated by AUC with Ishibashi's formula
Number of subjects: 15
Study 22610355 — intervention group
Group type: COMPARATOR
Intervention: CPT‐11 at a fixed dose of 60 mg/m2
Number of subjects: 15
Study 20455850 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador (mistletoe therapy)
Number of subjects: 0
Study 20455850 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone or any other best of care (not including Iscador)
Number of subjects: 0
Study 18627327 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatin-based combination chemotherapy
Number of subjects: 0
Study 18627327 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 16116008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% plus epinephrine 1:200,000
Number of subjects: 43
Study 16116008 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 43
Study 12195348 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine plus lamivudine
Number of subjects: 113
Study 12195348 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine plus abacavir
Number of subjects: 113
Study 12195348 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus abacavir
Number of subjects: 113
Study 12195348 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir (symptomatic children)
Number of subjects: 113
Study 12195348 — intervention group
Group type: COMPARATOR
Intervention: placebo (asymptomatic children)
Number of subjects: 113
Study 10189982 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community and community residences treatment environments
Number of subjects: 0
Study 10189982 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 0
Study 7584934 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (delapril)
Number of subjects: 1936
Study 7584934 — intervention group
Group type: COMPARATOR
Intervention: Ca antagonist
Number of subjects: 1936
Study 7584934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1936
Study 1691882 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg i.v.)
Number of subjects: 21
Study 1691882 — intervention group
Group type: COMPARATOR
Intervention: Morphatropin (1 ml s.c.)
Number of subjects: 21
Study 396336 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Port Chalmers (H3ChN2Ch) influenza vaccine (group A)
Number of subjects: 3
Study 396336 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraminidase-specific (Heq1N2Ch) influenza vaccine (group B)
Number of subjects: 3
Study 396336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3
Study 31089894 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored annular closure device (ACD)
Number of subjects: 554
Study 31089894 — intervention group
Group type: COMPARATOR
Intervention: Lumbar discectomy only (Control)
Number of subjects: 554
Study 28013097 — intervention group
Group type: EXPERIMENTAL
Intervention: Prequit Nicotine Patch
Number of subjects: 637
Study 28013097 — intervention group
Group type: EXPERIMENTAL
Intervention: Prequit Nicotine Gum
Number of subjects: 637
Study 28013097 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Person Counseling
Number of subjects: 637
Study 28013097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Prequit Gum and In-Person Counseling
Number of subjects: 637
Study 28013097 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal reduction and reduced prequit smoking
Number of subjects: 637
Study 25700931 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF23 levels
Number of subjects: 166
Study 25700931 — intervention group
Group type: EXPERIMENTAL
Intervention: FePi levels
Number of subjects: 166
Study 24129243 — intervention group
Group type: EXPERIMENTAL
Intervention: 40‐h dyadic and triadic communication skills training programme
Number of subjects: 95
Study 21217614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketorolac 10 mg plus submucous local tramadol (50 mg diluted in 1 mL saline solution)
Number of subjects: 30
Study 21217614 — intervention group
Group type: COMPARATOR
Intervention: Oral ketorolac 10 mg plus submucous local placebo (1 mL saline solution)
Number of subjects: 30
Study 19270300 — intervention group
Group type: EXPERIMENTAL
Intervention: RDTs performed by study staff
Number of subjects: 1827
Study 19270300 — intervention group
Group type: EXPERIMENTAL
Intervention: RDTs performed by health facility staff
Number of subjects: 1827
Study 19270300 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 1827
Study 16894413 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc(V)DMSA
Number of subjects: 31
Study 16894413 — intervention group
Group type: COMPARATOR
Intervention: (67)Ga‐C
Number of subjects: 31
Study 15271709 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 50
Study 15271709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11730183 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA flunisolide 170 microg, twice daily
Number of subjects: 669
Study 11730183 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA flunisolide 340 microg, twice daily
Number of subjects: 669
Study 11730183 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC flunisolide (250, 500, or 1,000 microg, twice daily)
Number of subjects: 669
Study 11730183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 669
Study 9473975 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural listening array with arm separations of 30 degrees, 45 degrees, and 60 degrees, signal-to-noise ratios of +5, -5, and -15 dB.
Number of subjects: 0
Study 9473975 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural listening array
Number of subjects: 0
Study 7935522 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG during fatigue protocol
Number of subjects: 11
Study 7935522 — intervention group
Group type: EXPERIMENTAL
Intervention: VMG during fatigue protocol
Number of subjects: 11
Study 7935522 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw EMG signals
Number of subjects: 11
Study 7935522 — intervention group
Group type: EXPERIMENTAL
Intervention: VMG records
Number of subjects: 11
Study 7935522 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency content of VMG signal
Number of subjects: 11
Study 3280532 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of MOPP and radiotherapy
Number of subjects: 66
Study 3280532 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 66
Study 29405670 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% 5 mL on radial and median nerves at the elbow (dNB group)
Number of subjects: 52
Study 29405670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distal nerve blocks)
Number of subjects: 52
Study 27930564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (DEX) 1 μg/kg over 10 minutes, followed by 0.5 μg/kg/h continuous infusion
Number of subjects: 60
Study 27930564 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% saline)
Number of subjects: 60
Study 24604142 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 40
Study 24604142 — intervention group
Group type: COMPARATOR
Intervention: Vestibular exercises
Number of subjects: 40
Study 23124178 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Therapy (SFT)
Number of subjects: 326
Study 23124178 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Term Psychodynamic Psychotherapy (SPP)
Number of subjects: 326
Study 23124178 — intervention group
Group type: COMPARATOR
Intervention: Long-Term Psychodynamic Psychotherapy (LPP)
Number of subjects: 326
Study 20969686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 55
Study 19046248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry treatment for 12 weeks
Number of subjects: 30
Study 19046248 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 30
Study 15010695 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg/day nicotine transdermal patch
Number of subjects: 9
Study 15010695 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal patch
Number of subjects: 9
Study 15010695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (15 and 30 mg/70 kg)
Number of subjects: 9
Study 15010695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (200 and 400 mg/70 kg)
Number of subjects: 9
Study 15010695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicotine (1.0 and 2.0 mg/70 kg)
Number of subjects: 9
Study 11273861 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding intervention in malnourished subjects
Number of subjects: 24
Study 11273861 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study 9550480 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (aCL) presence in patients with giant cell arteritis
Number of subjects: 284
Study 9550480 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 284
Study 9550480 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal arteritis biopsy positive
Number of subjects: 284
Study 9550480 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal arteritis biopsy negative
Number of subjects: 284
Study 9550480 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombotic complications associated with aCL
Number of subjects: 284
Study 8148435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention for chronic fatigue syndrome (CFS)
Number of subjects: 22
Study 8148435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention for primary depression
Number of subjects: 22